Case Series of Men with the Germline APCI1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer

•The APCI1307K germline variant is present in 7% of the Ashkenazi Jewish population and is associated with the development of several malignancies.•We report a case series of advanced prostate cancer patients with the germline APCI1307K mutation.•Prevalence of aggressive variant prostate cancer (driven by increased treatment-emergent neuroendocrine prostate cancer rate) in patients with the germline APCI1307K mutation is increased when compared to patients with prostate cancer and canonical APCframeshift mutations.•Prevalence of ARgenomic alterations in this cohort is lower than in unselected men with metastatic prostate cancer identified from cBioPortal database.